
    
      Treatment will be assigned by weight with subjects 20 kg to < 50 kg receiving apremilast 20
      mg BID or placebo BID and subjects â‰¥ 50 kg receiving apremilast 30 mg BID or placebo BID.
      Total study duration is up to 71 weeks. Subjects completing all 52 weeks of the treatment and
      extension phase will be able to enter the Long-term study. Subjects not entering the
      Long-term study will return for 3 observational follow-up visits, 4, 8 and 14 weeks after
      last dose of study drug.
    
  